Patient-Reported Outcomes, Patient-Reported Information From Randomized Controlled Trials to the Social Web and Beyond

被引:34
作者
Baldwin, Mike [1 ]
Spong, Andrew [2 ]
Doward, Lynda [3 ]
Gnanasakthy, Ari [4 ]
机构
[1] Novartis Horsham Res Ctr, Horsham RH12 5AB, W Sussex, England
[2] Nexus, London, England
[3] Galen Res Ltd, Manchester, Lancs, England
[4] Novartis Pharmaceut, E Hanover, NJ USA
关键词
Irritable Bowel Syndrome; Social Networking Site; Patient Community; Adult Growth Hormone Deficiency; Emergent Data;
D O I
10.2165/11585530-000000000-00000
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Internet communication is developing. Social networking sites enable patients to publish and receive communications very easily. Many stake-holders, including patients, are using these media to find new ways to make sense of diseases, to find and discuss treatments, and to give support to patients and their caregivers. We argue for a new definition of patient-reported information (PRI), which differs from the usual patient-reported outcomes (PRO). These new emergent data from the social web have important implications for decision making, at both an individual and a population level. We discuss new emergent technologies that will help aggregate this information and discuss how this will be assessed alongside the use of PROs in randomized controlled trials and how these new emergent data will be one facet of changing the relationship between the various stakeholders in achieving better co-created health.
引用
收藏
页码:11 / 17
页数:7
相关论文
共 21 条
[1]   Incorporating the patient's perspective into drug development and communication: An ad hoc task force report of the patient-reported outcomes (PRO) harmonization group meeting at the Food and Drug Administration, February 16, 2001 [J].
Acquadro, C ;
Berzon, R ;
Dubois, D ;
Leidy, NK ;
Marquis, P ;
Revicki, D ;
Rothman, M .
VALUE IN HEALTH, 2003, 6 (05) :522-531
[2]  
BERG S, 2006, BBC NEWS 0609
[3]  
BURKE L, 2000, DRUG INF ASS WORKSH
[4]   The use of patient-reported outcome measures in the evaluation of medical products for regulatory approval [J].
Burke, L. B. ;
Kennedy, D. L. ;
Miskala, P. H. ;
Papadopoulos, E. J. ;
Trentacosti, A. M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (02) :281-283
[5]  
Carmichael A, 6 SURPRISINGLY EFFEC
[6]  
CureTogether, CHRON OBSTR PULM DIS
[7]  
deBronkart D, EPATIENTDAVE
[8]   Requirements for quality of life instruments in clinical research [J].
Doward, LC ;
Meads, DM ;
Thorsen, H .
VALUE IN HEALTH, 2004, 7 :S13-S16
[9]  
Doward LC, 2004, VALUE HEALTH, V7, P4
[10]   Patient reported outcomes: looking beyond the label claim [J].
Doward, Lynda C. ;
Gnanasakthy, Ari ;
Baker, Mary G. .
HEALTH AND QUALITY OF LIFE OUTCOMES, 2010, 8